Groundbreaking Therapy Transforms Lives of Infants with Stroke
A revolutionary treatment approach has emerged, offering new hope for infants and toddlers affected by stroke. This innovative therapy, combining restricted use of the stronger arm with high-dose goal-directed therapy, has demonstrated remarkable results, sparking excitement and curiosity in the medical community.
Unlocking the Potential of High-Dose Therapy
For young stroke survivors, a novel treatment strategy has emerged as a game-changer. By limiting the use of their stronger arm and hand, these children were encouraged to utilize their stroke-affected side. When combined with a specific high-dose therapy, this approach led to immediate and significant improvements in function and skill acquisition.
The Study: A Comprehensive Approach
The research team conducted a study involving 167 stroke survivors under the age of 3, all with significant impairment in using one arm. These participants were randomly assigned to one of three treatment groups: a high dose of the new therapy, a moderate dose, or a continuation of their usual care.
Results: High-Dose Therapy Shines
After six months, the high-dose therapy group, known as I-ACQUIRE, showcased remarkable progress. These children exhibited larger gains in skills and daily function compared to their peers in the moderate-dose or usual care groups. But here's where it gets intriguing: even the usual care group, receiving standard occupational and physical therapy, showed significant improvements in arm and hand skills.
A Note on Study Status:
It's essential to note that this study is a research abstract, and the findings are considered preliminary. The American Heart Association's scientific meetings do not peer-review abstracts, and the results are not finalized until published in a peer-reviewed journal.
The Conference: A Platform for Breakthroughs
At the American Stroke Association's International Stroke Conference 2026, researchers presented these preliminary findings, sparking discussions and raising awareness about this groundbreaking therapy. The conference, held in New Orleans, is a premier event for stroke and brain health experts, providing a platform for the latest advancements in the field.
Perinatal Arterial Ischemic Stroke: A Common Challenge
Perinatal arterial ischemic stroke (PAIS) is the most prevalent form of stroke in children, leading to functional impairment and limited motor control on one side of the body, known as hemiparesis. This condition has long been a focus of research, seeking effective treatments to improve the lives of affected children.
Constraint-Induced Movement Therapy: Rewiring the Brain
Constraint-Induced Movement Therapy (CIMT) is a rehabilitation technique designed to enhance the use of an impaired upper extremity, helping the brain rewire itself after a stroke. In this study, CIMT was tailored for very young children, aiming to increase the use of their more-affected arm and hand. The therapy involved intensive motor training, guided by learning principles, to improve motor function and coordination in daily activities.
A First of Its Kind Study:
This research is the first to assess the impact of CIMT delivered in the child's natural environment, including a parent program to support infants and toddlers after perinatal strokes.
Filling the Knowledge Gap:
"This study addresses a critical knowledge gap," said Dr. Sharon Ramey, a leading researcher and co-director of the Fralin Biomedical Research Institute Neuromotor Research Clinic. "Previously, treatment recommendations for infants and toddlers with PAIS were based on studies of older children with cerebral palsy and hemiparesis. Our research provides specific data for this unique clinical population, confirming the safety and effectiveness of this treatment at both dosages."
The Clinical Trial: A Rigorous Evaluation
In a Phase 3 randomized clinical trial, researchers enrolled 216 children aged 8 to 36 months from 15 U.S. universities and hospitals. The study focused on three treatment groups: moderate-dose I-ACQUIRE therapy, high-dose I-ACQUIRE therapy, and usual care.
Treatment Details:
- Moderate-Dose I-ACQUIRE: Three hours of daily therapy, combined with constraint of the less-affected limb, for five days a week over four consecutive weeks.
- High-Dose I-ACQUIRE: Six hours of daily therapy with constraint of the less-affected arm and hand, five days a week for four weeks.
- Usual Care: Approximately one hour each of physical and occupational therapy per week, provided by community therapists.
Assessment and Results:
Certified assessors, unaware of the treatment groups, evaluated the children's arm and hand skills before, during, and after treatment. Parents also provided ratings of their child's functional performance in various home activities. The analysis revealed:
- Immediate Improvements: Both dose groups showed significant gains in neuromotor skills, with a median increase of 3 new skills each, compared to the usual care group's median gain of 1 skill.
- Long-Term Benefits: Children in the high-dose group demonstrated larger skill gains at six months post-treatment, with more apparent differences for those closely adhering to the therapy protocol.
- Real-World Impact: Parents reported meaningful improvements in their children's everyday use of the weaker arm and hand, including new skills like toy manipulation, communication gestures, and self-help abilities.
Unexpected Findings:
Interestingly, children in the usual care group also showed significant improvements in arm and hand skills at six months. However, parent ratings did not reflect real-world improvements in everyday use.
Unlocking the Mystery:
Dr. Ramey noted, "We expected more skills to be gained from I-ACQUIRE therapy. This finding suggests that children with PAIS may respond differently to the treatment, with some benefiting more than others. Identifying these individual responses will be crucial for future treatment plans."
Hope for the Future:
"Our research challenges the once-grim prognosis for infants with early strokes," Dr. Ramey added. "Parents reported seeing improvements beyond their expectations, leading to increased hope and higher goals for their children's future."
Study Strengths and Limitations:
The study demonstrated the feasibility of conducting such research and the effectiveness of the treatment plan. It focused on a specific group of young children, addressing a gap in previous research. However, limitations include the selection of U.S. sites based on interest and resources, potentially affecting representativeness. Additionally, a reduced sample size resulted from enrolling children with PAIS based on parental reports, which were not always confirmed by specialist review.
Study Details:
- Sample: 167 children, aged 8 to 36 months, with PAIS, from 15 U.S. cities.
- Treatment Groups: High-dose I-ACQUIRE (120 hours), moderate-dose I-ACQUIRE (60 hours), and usual care (2.2 hours weekly).
- Parent Option: Parents in the usual care group could opt for their child to receive I-ACQUIRE therapy after the six-month assessment by enrolling in the Delayed Treatment Study.
- Analysis and Oversight: Statisticians led the analysis, with a Data Safety and Monitoring Board overseeing the trial. An independent medical monitor was also appointed.
Funding and Disclosures:
The study received funding from the National Institute of Neurological Disorders and Stroke, and co-authors' disclosures are available in the abstract.
Association's Perspective:
The American Heart Association/American Stroke Association emphasizes that study findings presented at their scientific meetings are solely those of the authors and do not reflect the Association's policy. Abstracts are curated by review panels and considered for their potential to contribute to scientific discussions.
Association's Funding and Transparency:
The Association receives the majority of its funding from non-corporate sources, including individual contributions and investment earnings. They maintain strict policies to prevent donations from influencing scientific content and policy positions.
Additional Resources:
- Multimedia and links to the abstract and related resources are available on the right column of the release link.
- The American Heart Association's 2026 statistics highlight stroke as the #4 leading cause of death in the U.S.
- The Association's guidelines and news releases provide valuable insights into stroke management and its impact on children.
- Follow the American Stroke Association on X for the latest updates from the International Stroke Conference 2026.
About the American Stroke Association:
The American Stroke Association is dedicated to reducing strokes and promoting longer, healthier lives. They collaborate with volunteers and donors to ensure equitable stroke care and health across communities. Through research funding, advocacy, and lifesaving resources, they strive to prevent and overcome strokes.
Media and Expert Inquiries:
For media inquiries and expert perspectives, contact AHA Communications & Media Relations in Dallas or Karen Astle at Karen.Astle@heart.org.
Public Inquiries:
The public can reach out to the Association at 1-800-AHA-USA1 for inquiries.
